Genomate Health has been selected as a 2026 HLTH USA Startup Pitch finalist. Nabil Hafez, CEO, will take the stage to present how our computational reasoning technology can help identify treatment opportunities across precision oncology and cancer drug development. Joining Nabil in Las Vegas will be Dr. Istvan Petak, Founder and Chief Scientific Officer. Together, they look forward to meeting investors, healthcare leaders, and potential partners.

‍

Our work starts with a question that matters to patients, clinicians, and drug developers alike: which treatments could work for which patients, and why?

Genomate Health connects molecular evidence with an understanding of the biological mechanisms driving cancer. This approach supports the exploration of treatment options for individual patients and helps inform drug development, including identifying patient populations for new therapies, investigating additional uses for existing drugs, and reassessing assets that may hold promise in a different biological context.

Being selected as a Startup Pitch finalist gives us an opportunity to share this work with the wider healthcare community and explore partnerships to advance it.

‍

Attending HLTH USA? Come support Nabil’s pitch and get in touch to arrange a meeting ↗